Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Theradiag SA
  6. News
  7. Summary
    ALTER   FR0004197747

THERADIAG SA

(ALTER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Theradiag : enhances its oncology offer, with an 8th test in its Lisa-Tracker theranostic range: Avastin® test received CE marking (08 / 07 / 2014 )

07/21/2014 | 10:56am EDT
THERADIAG enhances its oncology offer, with an 8th test in its Lisa-Tracker theranostic range: Avastin® test received CE marking

Croissy-Beaubourg and Montpellier, 8 July 2014 - THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in in-vitro diagnostics and theranostics, today announces that its Lisa-Tracker range has been further expanded, with an 8th test receiving CE marking in oncology.
With the monitoring of the drug and of the anti-drug antibodies, this new test could optimize the treatment of patients on Avastin® (bevacizumab molecule). Avastin® is the only anti-angiogenic 1 therapy available for treating patients with advanced breast, colon, lung, kidney or ovarian cancer, which are responsible for more than 2.5 million deaths every year.
This kit, developed by Theradiag, is the Lisa-Tracker range's second test in oncology and will soon be marketed worldwide. It meets a major need from practitioners, with more than a million patients currently being treated with Avastin®. In 2013, sales of this drug totaled approximately 6.7 billion dollars (+8% compared with 2012). Furthermore, a vast program of more than 500 clinical trials is also currently underway and is looking into the possible use of Avastin® in around fifty additional types of tumor.

Michel Finance, CEO of THERADIAG, comments: "This 8th CE marked test is further proof of our commitment and our expertise in the development of the Lisa-Tracker range and our activity in theranostics. It enables us to expand our range and our activity to oncology. Further developments are ongoing, and will result in additional CE markings in 2014."

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of HIV/AIDS and rectal cancer. Theradiag is thus participating in the development of "customized treatment", which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-
Vallée, near Paris, and in Montpellier, and has over 60 employees.

1 Anti-angiogenic treatment: the use of drugs to inhibit angiogenesis, i.e. the production of blood vessels that irrigate cancerous tumors. The tumors, thus starved of blood, gradually disappear.

1/2

Theradiag

Investor Relations

Nathalie Trepo

Phone: +33 1 64 62 10 12

ntrepo@theradiag.com

NewCap.

Financial communications/

investor relations Valentine Brouchot / Pierre Laurent

Phone: +33 1 44 71 94 94 theradiag@newcap.fr

Alize RP

Press

Caroline Carmagnol theradiag@alizerp.com Phone: +33 6 64 18 99 59

2/2

distributed by

© Publicnow 2014
All news about THERADIAG SA
06/1010/06/2021 : Theradiag: report of the extraordinary general meeting on second ca..
PU
05/3131/05/2021 : Theradiag announces the launch of HUMABDIAG, a large-scale research..
PU
05/1010/05/2021 : Theradiag announces the adoption of all ordinary resolutions at the..
PU
04/1515/04/2021  : Mise à disposition du Rapport Financier annuel 2020 (only availabl..
PU
03/22THERADIAG  : Announces Its 2020 Full-year Results
BU
03/22THERADIAG  : Annual results
CO
02/0101/02/2021 : Theradiag posts 2020 revenue of 10.4 million, up 8.0%
PU
02/01THERADIAG  : Posts 2020 Revenue of €10.4 Million, up 8.0%
BU
02/01THERADIAG  : 4th quarter earnings
CO
01/1514/01/2021 : THERADIAG signs a contract to supply ORGENTEC with quality control ..
PU
More news
Financials
Sales 2021 - - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 2,80x
Yield 2021 -
Capitalization 17,6 M 20,9 M 20,9 M
Capi. / Sales 2021 -
EV / Sales 2022
Nbr of Employees 57
Free-Float 90,8%
Chart THERADIAG SA
Duration : Period :
Theradiag SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERADIAG SA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 2,70 €
Last Close Price 2,03 €
Spread / Highest target 33,0%
Spread / Average Target 33,0%
Spread / Lowest Target 33,0%
EPS Revisions
Managers and Directors
NameTitle
Bertrand Michel Marle de Castelnau Chief Executive Officer & Director
Fabienne François Chief Financial & Administrative Officer
Pierre Armand Morgon Chairman
Sylvie Bratel Independent Director
Vincent Fert Director
Sector and Competitors
1st jan.Capitalization (M$)
THERADIAG SA-21.62%21
EXACT SCIENCES CORPORATION-4.51%21 705
GUARDANT HEALTH, INC.-6.73%12 155
BGI GENOMICS CO., LTD.-7.47%7 557
INVITAE CORPORATION-21.57%6 553
ADAPTIVE BIOTECHNOLOGIES CORPORATION-33.28%5 535